Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News ProStrakan announces UK approval for Abstral

ProStrakan announces UK approval for Abstral

23rd September 2008

ProStrakan has announced that the UK Medicines and Healthcare Products Regulatory Agency has issued a marketing authorisation for Abstral (fentanyl) as a treatment for breakthrough cancer pain.

The company said this authorisation has come earlier than expected and will facilitate launch planning and UK pricing negotiations to be completed by the end of the year.

Consequently, the compound will be able to make a full contribution to the company’s sales figures for 2009.

Formerly known as Rapinyl, Abstral is a fast-dissolving tablet delivered sub-lingually administered to oncology patients who are already being treated with opioid analgesics.

The exclusive rights to the drug have been in-licensed by the company in Europe and North America from Orexo.

Dr Wilson Totten, chief executive of ProStrakan, said: “Abstral is an important product for cancer patients suffering from the debilitating effects of breakthrough pain and is expected to generate significant revenues for ProStrakan.”

He added the UK approval for the compound marks a major achievement for the company which will support its aim of achieving profitability by 2010.

Earlier this month, ProStrakan announced plans to launch Sancuso, its transdermal patch for the prevention of chemotherapy-induced nausea and vomiting, before the end of the year.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.